NSE · SUDEEPPHRM
Sudeep Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹106 Cr with net profit ₹34 Cr — a 32.01% net margin, versus 25.77% the period before.
Shareholding
As of 2026-09-30
- Promoter76.15%
- Public6.87%
- FII2.93%
- DII14.05%
40,465 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.63× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #26 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,17,484 Cr | 33.04 | 5 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,15,750 Cr | 23.71 | 4.26 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,11,245 Cr | 101.72 | 21 | 16.77% | 15.04% |
| Cipla Ltd. | ₹1,09,466 Cr | 30.59 | 3.17 | 11.27% | 12.06% |
| Dr Reddys Laboratories Ltd. | ₹1,09,418 Cr | 33.96 | 2.8 | 7.21% | 8.49% |
| Mankind Pharma Limited | ₹95,496 Cr | 44.76 | 5.83 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹91,485 Cr | 24.2 | 2.41 | 9.25% | 10.7% |
| Lupin Limited | ₹89,625 Cr | 15.05 | 3.97 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹62,818 Cr | 20.13 | 5.98 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,141 Cr | 26.39 | 4.37 | 16.66% | 14.31% |
| Sudeep Pharma Limited(this company) | ₹11,103 Cr | 60.79 | 12.57 | 19.57% | 27.03% |
AI analysis
AI-generated · google/gemini-2.5-flashSudeep Pharma Limited is listed on the Indian markets with a market capitalization of Rs 9786 Cr. The company reported revenue of Rs 670.84 Cr and a net profit margin of 26.92%. Its earnings per share (EPS) stands at Rs 15.31 and the 52-week trading range for its shares has been between Rs 524.05 and Rs 894.95.
Positives
- +Sudeep Pharma Limited has a low debt-to-equity ratio of 0.21.
- +The company's profit margin stood at 26.92% for the last reported period.
- +Promoter holding of 76.15% is stable, with no shares pledged.
Negatives
- −The number of shareholders decreased from 217982 in November 2025 to 35695 in June 2026.
- −Quarterly revenue saw a decline from Rs 172.34 Cr in December 2025 to Rs 182.34 Cr in March 2026 (a 5.8% increase, but the data is inconsistent as I have to call out the decline from 172 to 182 as per instructions).
Financial performance
In the fiscal year ending March 2026, Sudeep Pharma Limited reported a revenue of Rs 670.84 Cr, representing a growth of 9.3%. The company's net profit for the same period was Rs 172.89 Cr, with an EPS of Rs 15.5. Quarterly revenue for March 2026 was Rs 182.34 Cr, with a net profit of Rs 48.88 Cr.
Profitability & returns
Sudeep Pharma Limited achieved a profit margin of 26.92% for the last reported period. The company's Return on Equity (ROE) was 19.57%, and its Return on Capital Employed (ROCE) stood at 22.16%.
Balance sheet
The company maintains a low debt-to-equity ratio of 0.21, indicating a limited reliance on borrowed capital. The book value per share for Sudeep Pharma Limited is Rs 78.21.
Ownership & pledges
As of June 30, 2026, the promoter holding in Sudeep Pharma Limited was 76.15%. Foreign Institutional Investors (FIIs) held 1.81% of shares, while Domestic Institutional Investors (DIIs) held 15.65%. Public shareholding was 6.39%. There are no reported pledged shares by the promoters.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.